Gilead Drug Patent Portfolio
Gilead owns 5 orange book drugs protected by 36 US patents with Hepsera having the least patent protection, holding only 2 patents. And Truvada with maximum patent protection, holding 21 patents. Given below is the list of Gilead's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9549926 | Compositions and methods of treating pulmonary hypertension | 14 Oct, 2031 | Active |
| US8377933 | Method for treating a pulmonary hypertension condition | 11 Dec, 2027 | Active |
| US9474752 | Method for treating a pulmonary hypertension condition | 11 Dec, 2027 | Active |
| US8716264 | Compositions and methods for combination antiviral therapy | 13 Jul, 2024 | Expired |
| US8592397 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US8716264 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US9457036 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US9744181 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US7208141 | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections | 20 Dec, 2021 | Expired |
| US7214364 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | 20 Dec, 2021 | Expired |
| US7427633 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | 20 Dec, 2021 | Expired |
| US8399496 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections | 20 Dec, 2021 | Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Sep, 2021 | Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 May, 2021 | Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Mar, 2021 | Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 Nov, 2020 | Expired |
| USRE42462 | Carboxylic acid derivatives, their preparation and use | 29 Jul, 2018 | Expired |
| US6451340 | Nucleotide analog compositions | 23 Jul, 2018 | Expired |
| US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | 25 Jan, 2018 | Expired |
| US5935946 | Nucleotide analog composition and synthesis method | 25 Jan, 2018 | Expired |
| US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jan, 2018 | Expired |
| US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jan, 2018 | Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 02 Jan, 2018 | Expired |
| US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | 25 Jul, 2017 | Expired |
| US5935946 | Nucleotide analog composition and synthesis method | 25 Jul, 2017 | Expired |
| US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jul, 2017 | Expired |
| US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jul, 2017 | Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 02 Jul, 2017 | Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds | 29 Mar, 2016 | Expired |
| US5840722 | Use of carboxylic acid derivatives as drugs | 24 Nov, 2015 | Expired |
| US7109205 | Carboxylic acid derivatives, their preparation and use | 07 Oct, 2015 | Expired |
| US7601730 | Carboxylic acid derivatives, their preparation and use | 07 Oct, 2015 | Expired |
| US8349843 | Carboxylic acid derivatives, their preparation and use | 07 Oct, 2015 | Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds | 29 Sep, 2015 | Expired |
| US5703017 | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation | 30 Dec, 2014 | Expired |
| US5663159 | Prodrugs of phosphonates | 02 Sep, 2014 | Expired |
Latest Legal Activities on Gilead's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Gilead.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549926 |
|
Expire Patent
Critical
| 15 Feb, 2021 | US8349843 |
|
Maintenance Fee Reminder Mailed
Critical
| 31 Aug, 2020 | US8349843 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Aug, 2020 | US8377933 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Jul, 2020 | US9549926 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Mar, 2020 | US7427633 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Nov, 2018 | US7214364 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Oct, 2018 | US7208141 |
|
Expire Patent
Critical
| 22 Oct, 2018 | US7109205 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 30 Apr, 2018 | US7109205 (Litigated) |
|
Expire Patent
Critical
| 13 Nov, 2017 | US7601730 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Jan, 2017 | US9549926 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jan, 2017 | US9549926 |
|
Email Notification
Critical
| 06 Jan, 2017 | US9549926 |
|
Issue Notification Mailed
Critical
| 04 Jan, 2017 | US9549926 |
Gilead's Drug Patent Litigations
Gilead's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Gilead's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5935946 | June, 2014 |
Terminated-Denied
(17 Dec, 2014)
| Gilead Sciences, Inc. | MYLAN PHARMACEUTICALS INC. |
| US5922695 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
| US5977089 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
| US6043230 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
| US6703396 | April, 2002 |
Decision
(04 Apr, 2002)
| DIONNE | |
| US6642245 | July, 2001 |
Decision
(05 Jul, 2001)
| DIONNE | |
Gilead Drug Patents' Oppositions Filed in EPO
Gilead drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 13, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04701819A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP11833507A | Dec, 2017 | SANDOZ AG | Revoked |
| EP11833507A | Dec, 2017 | Zentiva Group, a.s. | Revoked |
| EP11833507A | Dec, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP11833507A | Dec, 2017 | Generics (U.K.) Limited | Revoked |
| EP11833507A | Dec, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP11833507A | Dec, 2017 | STADA Arzneimittel AG | Revoked |
| EP07855065A | Feb, 2016 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP07855065A | Feb, 2016 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Revoked |
| EP04701819A | Mar, 2009 | Generics [UK] Limited | Revoked |
| EP04701819A | Mar, 2009 | Teva Pharmaceutical Industries LTD. | Revoked |
Gilead's Family Patents
Gilead drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 24.6% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Gilead Drug List
Given below is the complete list of Gilead's drugs and the patents protecting them.
1. Cayston
Cayston is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7208141 | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
20 Dec, 2021
(2 years ago)
| Expired |
| US7214364 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
20 Dec, 2021
(2 years ago)
| Expired |
| US7427633 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
20 Dec, 2021
(2 years ago)
| Expired |
| US8399496 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
20 Dec, 2021
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cayston's drug page
2. Emtriva
Emtriva is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
| US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
| US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
| US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emtriva's drug page
3. Hepsera
Hepsera is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6451340 | Nucleotide analog compositions |
23 Jul, 2018
(6 years ago)
| Expired |
| US5663159 | Prodrugs of phosphonates |
02 Sep, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hepsera's drug page
4. Letairis
Letairis is protected by 9 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9549926 | Compositions and methods of treating pulmonary hypertension |
14 Oct, 2031
(6 years from now)
| Active |
| US8377933 | Method for treating a pulmonary hypertension condition |
11 Dec, 2027
(3 years from now)
| Active |
| US9474752 | Method for treating a pulmonary hypertension condition |
11 Dec, 2027
(3 years from now)
| Active |
| USRE42462 | Carboxylic acid derivatives, their preparation and use |
29 Jul, 2018
(6 years ago)
| Expired |
| US5840722 | Use of carboxylic acid derivatives as drugs |
24 Nov, 2015
(8 years ago)
| Expired |
| US7109205 | Carboxylic acid derivatives, their preparation and use |
07 Oct, 2015
(9 years ago)
| Expired |
| US7601730 | Carboxylic acid derivatives, their preparation and use |
07 Oct, 2015
(9 years ago)
| Expired |
| US8349843 | Carboxylic acid derivatives, their preparation and use |
07 Oct, 2015
(9 years ago)
| Expired |
| US5703017 | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
30 Dec, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Letairis's drug page
5. Truvada
Truvada is protected by 21 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8716264
(Pediatric)
| Compositions and methods for combination antiviral therapy |
13 Jul, 2024
(3 months ago)
| Expired |
| US8592397 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(9 months ago)
| Expired |
| US8716264 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(9 months ago)
| Expired |
| US9457036 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(9 months ago)
| Expired |
| US9744181 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(9 months ago)
| Expired |
| US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
| US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
| US5922695
(Pediatric)
| Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jan, 2018
(6 years ago)
| Expired |
| US5935946
(Pediatric)
| Nucleotide analog composition and synthesis method |
25 Jan, 2018
(6 years ago)
| Expired |
| US5977089
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
| US6043230
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
| US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
| US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jul, 2017
(7 years ago)
| Expired |
| US5935946 | Nucleotide analog composition and synthesis method |
25 Jul, 2017
(7 years ago)
| Expired |
| US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
| US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
| US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Truvada's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List